Sanofi trial failure halts work on breast cancer treatment amcenestrant

Sanofi has stopped further work on amcenestrant, a treatment once seen to have strong commercial potential in breast cancer, after a second trial failure dealt a major blow to the French healthcare company’s development prospects. The move weighed on shares and mounted pressure on Sanofi to bolster its pipeline of drug candidates as it becomes […]